Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses Yazar: Ernesto Gargiulo (15134961)

Konular:

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Yazar: Elizabeth R. Tucker (15053624)

Konular:

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses Yazar: Ernesto Gargiulo (15134961)

Konular:

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Yazar: Elizabeth R. Tucker (15053624)

Konular:

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Yazar: Elizabeth R. Tucker (15053624)

Konular:

Supplementary Table S3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses Yazar: Ernesto Gargiulo (15134961)

Konular:

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models Yazar: Elizabeth R. Tucker (15053624)

Konular:

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans Yazar: Yuanqing Ma (15052437)

Konular:

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans Yazar: Yuanqing Ma (15052437)

Konular:

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans Yazar: Yuanqing Ma (15052437)

Konular:

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans Yazar: Yuanqing Ma (15052437)

Konular:

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans Yazar: Yuanqing Ma (15052437)

Konular:

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans Yazar: Yuanqing Ma (15052437)

Konular:

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans Yazar: Yuanqing Ma (15052437)

Konular:

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans Yazar: Yuanqing Ma (15052437)

Konular:

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma Yazar: Alyssa C. Flint (16676029)

Konular:

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma Yazar: Alyssa C. Flint (16676029)

Konular:

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Yazar: Erika Y. Faraoni (14844897)

Konular:

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Yazar: Erika Y. Faraoni (14844897)

Konular:

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma Yazar: Nicholas T. Younger (14956251)

Konular: